As Dew mentioned, the clown show is the over extrapolation of the data, not the data itself—as well as the herd mentality exhibited by most fund managers. Peloton stock was up today on this news.
It's gotten a bit ridiculous that every new data point about GLP-1 causes this kind of overreaction. We know that GLP-1 drugs cause people to lose weight and being overweight has broad implications.
Given the above there's really an endless number of successful studies you could run with these drugs. How about a study to determine if Ozempic improves this guy's mile time. Buy NKE?